Table 2 Overall baseline characteristics according to liver disease stage
Parameters | Cirrhosis (n = 731) | Advanced liver fibrosis (n = 254) |
|---|---|---|
Sex, n (%) | ||
M | 391 (53.5) | 152 (59.8) |
F | 340 (46.5) | 102 (40.2) |
Age, years, median [IQR] | 68 [60–74] | 66 [58–72] |
BMI, kg/m2, median [IQR] | 26 [23.9–28.4] | 26.1 [24.1–28.3] |
Diabetes, n (%) | 99 (13.6) | 32 (12.6) |
Metabolic syndrome, n (%) | 53 (8.2) | 16 (7.5) |
Child–Turcotte–Pugh, n (%) | ||
Class A | 649 (88.8) | – |
Class B | 82 (11.2) | – |
HCV genotype, n (%) | ||
1 | 561 (76.7) | 205 (80.7) |
2 | 121 (16.6) | 38 (15) |
3 | 43 (5.9) | 7 (2.8) |
4 | 6 (0.8) | 4 (1.6) |
Liver stiffness, kPa, median [IQR] | 21 [15.6–27.2] | 10.7 [10–11.8] |
Treatment duration, n (%) (weeks) | ||
12 | 401 (54.9) | 211 (83.1) |
24 | 330 (45.1) | 43 (16.9) |
SVR12, n (%) | 714 (97.7) | 252 (99.2) |
DAAs regimen, n (%) | ||
SOF/RBV | 322 (44) | 96 (37.8) |
SOF/LDV ± RBV | 158 (21.6) | 31 (12.2) |
SOF/DCV ± RBV | 26 (3.6) | 7 (2.8) |
SOF/SIM ± RBV | 78 (10.7) | 21 (8.3) |
2D/3D ± RBV | 147 (20.1) | 109 (39) |
Treatment classes, n (%) | ||
SOF based | 584 (79.9) | 154 (60.6) |
RBV included | 549 (75.1) | 156 (24.2) |
SOF/RBV | 450 (61.6) | 123 (48.4) |
HCC occurrence, n (%) | 35 (4.8) | 0 (0) |